Lawsuit for Investors in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) announced by Shareholders Foundation

Monday, January 23, 2017 2:45 PM UTC

SAN DIEGO, Jan. 23, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Seattle Genetics, Inc. (NASDAQ:SGEN) over alleged Securities Laws Violations by Seattle Genetics.

Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ: SGEN) have certain options and for certain investors there are short and strict deadlines running. Deadline: March 13, 2017. NASDAQ: SGEN investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that vadastuximab talirine presents a significant risk of fatal hepatotoxicity, that as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia (AML) treatment, and that as a result of the foregoing, Seattle Genetics’ public statements were materially false and misleading at all relevant times.

On December 27, 2016, Seattle Genetics, Inc. announced that it has received notice from the U.S. Food and Drug Administration (“FDA“) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML).

Those who purchased Seattle Genetics, Inc. (NASDAQ: SGEN) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:  Shareholders Foundation, Inc.
          Michael Daniels
          +1 (858) 779-1554
          [email protected]
          3111 Camino Del Rio North
          Suite 423
          San Diego, CA 92108

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Lawsuit for Investors in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) announced by Shareholders Foundation

Editor's Picks

Welcome to EconoTimes